(Total Views: 682)
Posted On: 08/28/2019 4:55:09 PM
Post# of 1460
Below a copy from IHUB,
Fletch
falconer66a Wednesday, 08/28/19 03:03:29 PM
Re: baltimorebullet post# 207601 0
Post # of 207621
Yes, Watching Closely
Quote:
Falconer, are you still out there?
Yes, I read almost every posting closely (except for the clownish ones). Nothing for me, personally, to post about, until just now. (Thanks for the prompt.)
I’m still digesting the load of information in this new journal article, Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases
https://www.frontiersin.org/articles/10.3389/...00_ARTICLE
A number of us have long contended that restoration or promotion of sigma-1 receptor functions will have exceedingly diverse, favorable results for a multitude of central nervous system and other diseases in humans (well, in all vertebrates; the unstated veterinary opportunities).
For those questioning the targeted human pathologies in the Anavex pipeline (which include: Alzheimer's Disease, Parkinson's Disease Dementia, Rett Syndrome, Infantile Spasms, Fragile X, Angelman's, Frontotemporal Dementia, Depression, Stroke, Visceral Pain, Acute and Neuropathic Pain, and Prostate and Pancreatic Cancer), the referenced new paper delineates how the biology and physiology of the sigma-1 receptors can have so many useful facilitations.
For those who question the broad, diverse therapeutic applications of the Anavex sigma-1 receptor agonists, force yourself to read the entire article (even if you can’t comprehend what’s being stated). Simply, the article verifies the multitude of clinical applications for the unique Anavex molecules. They are, to an extent, a fix-everything sort of chemical therapy.
Those familiar with my postings some time ago will recall that I’ve contended from early on that Missling and his cohorts know full well the gigantic number of clinical applications for the company’s molecules. It’s far more than just Rett, Parkinson’s, or Alzheimer’s. Those are just the start of the Anavex revolution in 21st-century medicine — as the data and information in the new paper support. Fixing sigma-1 receptor dysfunctions fixes everything happening metabolically or physiologically downstream. Big; as we will learn in the coming months and years. Certainly, dozens upon dozens of transgenic Anavex-treated rats have had their health restored. Missling, et al. know what they have. The new article reveals the biochemical basis for Anavex treatments of diverse diseases and conditions.
Respond | View Replies (3)
https://investorshub.advfn.com/boards/replies...=150810000
Fletch
falconer66a Wednesday, 08/28/19 03:03:29 PM
Re: baltimorebullet post# 207601 0
Post # of 207621
Yes, Watching Closely
Quote:
Falconer, are you still out there?
Yes, I read almost every posting closely (except for the clownish ones). Nothing for me, personally, to post about, until just now. (Thanks for the prompt.)
I’m still digesting the load of information in this new journal article, Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases
https://www.frontiersin.org/articles/10.3389/...00_ARTICLE
A number of us have long contended that restoration or promotion of sigma-1 receptor functions will have exceedingly diverse, favorable results for a multitude of central nervous system and other diseases in humans (well, in all vertebrates; the unstated veterinary opportunities).
For those questioning the targeted human pathologies in the Anavex pipeline (which include: Alzheimer's Disease, Parkinson's Disease Dementia, Rett Syndrome, Infantile Spasms, Fragile X, Angelman's, Frontotemporal Dementia, Depression, Stroke, Visceral Pain, Acute and Neuropathic Pain, and Prostate and Pancreatic Cancer), the referenced new paper delineates how the biology and physiology of the sigma-1 receptors can have so many useful facilitations.
For those who question the broad, diverse therapeutic applications of the Anavex sigma-1 receptor agonists, force yourself to read the entire article (even if you can’t comprehend what’s being stated). Simply, the article verifies the multitude of clinical applications for the unique Anavex molecules. They are, to an extent, a fix-everything sort of chemical therapy.
Those familiar with my postings some time ago will recall that I’ve contended from early on that Missling and his cohorts know full well the gigantic number of clinical applications for the company’s molecules. It’s far more than just Rett, Parkinson’s, or Alzheimer’s. Those are just the start of the Anavex revolution in 21st-century medicine — as the data and information in the new paper support. Fixing sigma-1 receptor dysfunctions fixes everything happening metabolically or physiologically downstream. Big; as we will learn in the coming months and years. Certainly, dozens upon dozens of transgenic Anavex-treated rats have had their health restored. Missling, et al. know what they have. The new article reveals the biochemical basis for Anavex treatments of diverse diseases and conditions.
Respond | View Replies (3)
https://investorshub.advfn.com/boards/replies...=150810000
(2)
(0)Scroll down for more posts ▼
